AIM ImmunoTech expands Ampligen long COVID patent coverage through 2041
AIM ImmunoTech expands its Ampligen® global patent estate for long COVID protection in Europe and the United Kingdom through 2041.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.